Document is current
Any future updates will be listed below
-
Authors
Brastianos, Priscilla K.
Strickland, Matthew R.
Lee, Eudocia Quant
Wang, Nancy
Cohen, Justine V.
Chukwueke, Ugonma
Forst, Deborah Anne
Eichler, April
Overmoyer, Beth
Lin, Nancy U.
Chen, Wendy Y.
Bardia, Aditya https://orcid.org/0000-0003-4885-1157
Juric, Dejan https://orcid.org/0000-0003-2983-7704
Dagogo-Jack, Ibiayi
White, Michael D. https://orcid.org/0000-0002-3855-9243
Dietrich, Jorg
Nayyar, Naema https://orcid.org/0000-0003-3436-8404
Kim, Albert E. https://orcid.org/0000-0003-2359-6209
Alvarez-Breckenridge, Christopher
Mahar, Maura
Mora, Joana L. https://orcid.org/0000-0002-5913-1107
Nahed, Brian V.
Jones, Pamela S.
Shih, Helen A.
Gerstner, Elizabeth R.
Giobbie-Hurder, Anita
Carter, Scott L. https://orcid.org/0000-0002-8480-1475
Oh, Kevin
Cahill, Daniel P.
Sullivan, Ryan J. https://orcid.org/0000-0001-5344-6645
-
Funding
Funding for this research was provided by:
Breast Cancer Research Foundation
Damon Runyon Cancer Research Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Melanoma Research Alliance
- License Information
-
More Information
Article History
Received: 14 November 2020
Accepted: 25 August 2021
First Online: 12 October 2021
Competing interests
: P.K.B. has received compensation for consulting from Lilly, Angiochem, ElevateBio, Voyager Therapeutics, Tesaro, Genentech-Roche, SK Life Sciences, Pfizer, Dantari and Speaker’s Honoraria from Genentech-Roche and Merck Sharp & Co. P.K.B. has received research funding (to MGH) from Merck & Co, BMS, Eli Lilly, Mirati and Pfizer. J.V.C. has received consulting fees from Sanofi-Genzyme and BMS. D.P.C. has consulted for Lilly and Boston Pharmaceuticals, and has received travel/speaking fees from Merck. N.U.L. has received institutional research funding from Seattle Genetics, Genentech, Merck, and Pfizer. She has served on an advisory board or consulted for PUMA Biotechnology, Seattle Genetics, and Daichii Sankyo. R.J.S. has received research funding from Amgen and Merck, and served as a paid consultant and/or on an advisory board for Array BioPharma, Amgen, Asan Biosciences, BMS, Compugen, Genentech, Merck, Novartis, and Replimmune. E.Q.L. has received royalties from Wolters Kluwers (Up to Date, Inc) and has consulted for Lilly. M.D.W. is a consultant at Boston Pharmaceuticals. I.D.J. has received honoraria from Foundation Medicine, consulting fees from Boehringer Ingelheim and AstraZeneca, travel fees from Array and Pfizer, and research support from Array, Genentech, Guardant, and Pfizer. J.D. is a consultant for Unum Therapeutics and Blue Earth Diagnostics and has received royalties from Kluwer Wolters. A.B. reports grants from Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics, Biothernostics Inc. and personal fees from Biothernostics Inc., Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics, Taiho, Sanofi, Diiachi Pharma/Astra Zeneca, Puma, Phillips, Eli Lilly and Foundation Medicine, outside the submitted work. B.O. has received clinical trial support from Eisai and Incyte. D.F. holds shares in Eli Lilly. All other authors declare no competing interests.
